Skye Bioscience, Inc.

Healthcare · Biotechnology · United States

Last price 1.31 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.80M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses met...